MOTS-c
Also known as Mitochondrial ORF of the 12S rRNA type-c
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, described in 2015. It belongs to a family of mitochondrial-derived peptides studied for their role in metabolism. It is not an approved drug.
By [Author name]. Licensed pharmacist review: pending. Last updated .
Identity
- Sequence
- Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (MRWQEMGYIFYPRKLR)
- Length
- 16 amino acids
- Molecular formula
- C101H152N28O22S2 (PubChem)
- Molar mass
- about 2,175 g/mol
What the research covers
Lee and colleagues described MOTS-c in Cell Metabolism in 2015, reporting effects on glucose and fat metabolism in mice and in cell models.
Most later work is in mice and cells, looking at exercise capacity, insulin sensitivity and aging models. An analog of MOTS-c entered early-stage clinical testing by a biotech company, but no approval resulted.
Summaries describe what studies measured, not what a substance does for anyone. Nothing here is a claim of benefit or a basis for use.
Regulatory status
- Not FDA-approved.
- A 2026 PCAC vote recommended MOTS-c for the 503A bulks list, and the October 15, 2026 interim access policy draft names it. Neither was final as of the review date.
Anti-doping (WADA)
Not approved for human use, so it falls under WADA's S0 (non-approved substances). Check the current list for any specific naming.
Follow changes on the FDA peptide status tracker.
MOTS-c questions
Is MOTS-c made by the body?
Yes. It is encoded in mitochondrial DNA and found in human plasma and tissues. Synthetic MOTS-c sold in vials is made by peptide synthesis.